TrademarkDir
NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES
DEAD

Serial Number

88730797

Owner

Angiex, Inc.

Attorney

Susanna P. Lichter

First Use Date

Jan 10, 2020

Filing Date

Dec 17, 2019

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES Trademark

Serial Number: 88730797

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES is a trademark filed by Angiex, Inc. on December 17, 2019. The trademark is classified under Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Angiex, Inc. (8 trademarks)

393 Broadway, #15
Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

December 17, 2019

Registration Date

Not Registered

First Use Anywhere

January 10, 2020

First Use in Commerce

January 10, 2020

Goods & Services

Scientific research and development in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; research and product development services for others in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine; Medical and scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, and cardiovascular disease detection; Providing information on the subject of scientific research in the fields of cancer, immunological-inflammatory conditions, tissue repair, eye diseases, cardiovascular disease, biology, laboratory testing, biotechnology, biochemistry, and medicine

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 7, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 7, 2022 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 3, 2021 GNFN
FINAL REFUSAL E-MAILED
Sep 3, 2021 GNFR
FINAL REFUSAL WRITTEN
Sep 3, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 16, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 16, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 9, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 10, 2021 GNRN
NON-FINAL ACTION E-MAILED
Feb 10, 2021 GNRT
NON-FINAL ACTION WRITTEN
Feb 10, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 25, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2021 CRFA
ASSIGNED TO LIE
Jan 22, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 12, 2020 TROA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Apr 14, 2020 AAUA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 13, 2020 GNRN
NON-FINAL ACTION E-MAILED
Apr 13, 2020 GNRT
NON-FINAL ACTION WRITTEN
Apr 13, 2020 CNRT
USE AMENDMENT ACCEPTED
Apr 12, 2020 IUAA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 2, 2020 TEME
AMENDMENT TO USE PROCESSING COMPLETE
Apr 2, 2020 AUPC
USE AMENDMENT FILED
Apr 2, 2020 IUAF
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2020 TROA
TEAS AMENDMENT OF USE RECEIVED
Apr 1, 2020 EAAU
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 17, 2020 GNRN
NON-FINAL ACTION E-MAILED
Mar 17, 2020 GNRT
NON-FINAL ACTION WRITTEN
Mar 17, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 16, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 20, 2019 NWOS
NEW APPLICATION ENTERED
Dec 20, 2019 NWAP

Related Trademarks

More from this Owner

Trademark logo

Serial #98503129

Trademark logo

Serial #98503129

Trademark logo

Serial #98503129

NUCLEAR DELIVERY PLATFORM

NUCLEAR DELIVERY PLATFORM

NUCLEAR DELIVERY PLATFORM

NUCLEAR DELIVERY PLATFORM

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES

NUCLEAR-DELIVERED ANTIBODY-DRUG CONJUGATES